Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Stock data | 2023 | Change |
---|---|---|
Price | $5.29 | N/A |
Market Cap | $62.25M | N/A |
Shares Outstanding | 11.76M | 6.94% |
Employees | 24.00 | N/A |
Shareholder Equity | 2.40B | -23.97% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.08 | N/A |
P/S Ratio | 97.00 | N/A |
P/B Ratio | 0.03 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0022 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $641.74K | N/A |
Earnings | -$5.36M | N/A |
EPS | -66.93 | N/A |
Earnings Yield | -12.64 | N/A |
Gross Margin | 0.9186 | N/A |
Operating Margin | -7.41 | N/A |
Net income margin | -8.35 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $17.49M | N/A |
Cash on Hand | $16.66M | N/A |
Debt to Equity | 0.0005 | 50.79% |
Current Ratio | $22.63 | 2.05% |